Eloralintide 5mg Pen – Research Peptide UK

Eloralintide 5mg Pen from N&A Peptides is presented as a research material for laboratory, analytical and scientific investigations. Eloralintide, also known by its development identifier LY3841136, is an investigational peptide being developed by Eli Lilly and Company. It belongs to a class of compounds known as selective amylin receptor agonists. Eloralintide has attracted scientific interest because of its selective activity at amylin receptors, particularly the AMY1 receptor. Researchers are investigating the relationship between amylin signalling, metabolic regulation, appetite-related biological pathways and energy balance. The Eloralintide 5mg Pen provides a clearly labelled research presentation containing a nominal 5mg quantity. It is intended strictly for qualified scientific and laboratory research and is not an approved medicine.

Eloralintide 5mg Pen – Product Specifications

• Product: Eloralintide 5mg Pen
• Compound: Eloralintide
• Research identifier: LY3841136
• Nominal quantity: 5mg
• Presentation: Research pen
• Compound class: Selective amylin receptor agonist
• Research focus: Amylin receptor signalling and metabolic research
• Intended application: Laboratory and analytical research only
• Restriction: Not for human or veterinary use

Explore additional laboratory research materials in the N&A Peptides UK research collection.

What Is Eloralintide?

Eloralintide is an investigational synthetic peptide developed to selectively activate amylin receptors. Amylin is a naturally occurring hormone associated with pancreatic endocrine signalling and the physiological regulation of food intake. Unlike GLP-1 receptor agonists, which primarily target glucagon-like peptide-1 signalling, eloralintide is designed to act through the amylin receptor system. This difference makes the compound an interesting subject for researchers examining separate but potentially complementary metabolic signalling pathways. Eli Lilly identifies eloralintide as a selective amylin receptor agonist with preferential activity at the AMY1 receptor. For further scientific background, visit Eli Lilly's official Eloralintide research information.

Eloralintide and Amylin Receptor Research

Amylin is a peptide hormone released alongside insulin from pancreatic beta cells. It participates in biological signalling associated with nutrient intake, gastric function and energy homeostasis. Research into selective amylin receptor agonists seeks to improve scientific understanding of the following areas:

• Amylin receptor activation and cellular signalling
• AMY1 receptor selectivity
• Metabolic hormone communication
• Satiety-associated signalling pathways
• Interactions between amylin and incretin receptor systems
• Long-acting peptide receptor pharmacology

Eloralintide is being investigated within this wider area of metabolic research. Findings from clinical studies relate to the specific investigational medicine used in those trials and should not be assumed to apply to independently supplied research materials.

Eloralintide Clinical Research and Scientific Studies

Eloralintide has been investigated in controlled clinical research, including a 48-week Phase 2 study involving 263 participants with obesity or overweight and at least one related health condition. The study examined several experimental treatment groups and evaluated changes in body weight, tolerability and safety under clinical supervision. The results were published in The Lancet in 2025 and contributed to the ongoing scientific understanding of selective amylin receptor agonism. Researchers can review the peer-reviewed publication here: The Lancet – Eloralintide Phase 2 Clinical Trial. Eli Lilly has subsequently advanced eloralintide into Phase 3 clinical development. These ongoing studies aim to gather further evidence about the investigational compound's efficacy and safety. Eloralintide remains investigational. Clinical research results do not represent regulatory approval, and the research product listed here has not been demonstrated to be equivalent to the pharmaceutical formulation used in clinical trials.

Eloralintide Compared With Other Research Peptides

Eloralintide is scientifically distinct from several other investigational peptides studied in metabolic research.

Eloralintide and Retatrutide

Eloralintide is primarily investigated for selective amylin receptor activity. Retatrutide, by comparison, is a triple receptor agonist being studied for activity at GLP-1, GIP and glucagon receptors. Both compounds have attracted scientific interest, but they interact with different receptor systems and have different investigational mechanisms. Researchers interested in contrasting these pathways can explore our Retatrutide 50mg Vial research information.

Eloralintide and Incretin Research

Amylin receptor signalling is also being studied alongside incretin pathways. Researchers are examining whether these biological systems may have complementary roles in metabolic regulation. Eli Lilly has investigated eloralintide in combination with tirzepatide in clinical research under the investigational programme known as EloraTZP. These studies are conducted using carefully defined pharmaceutical preparations under clinical protocols. Their findings should not be extrapolated to unsupervised combinations of research products.

Eloralintide 5mg Pen – Research Presentation

The Eloralintide 5mg Pen is supplied in a pen-style research presentation with the compound name and stated quantity clearly identified. Clear product identification helps laboratories organise research materials, maintain sample records and distinguish compounds used in separate analytical investigations. Researchers should confirm the applicable batch details, analytical documentation and product-specific storage information before incorporating any material into laboratory work.

Quality, Analytical Testing and Documentation

At N&A Peptides, we recognise the importance of clear product information and transparent analytical documentation. Where available, a Certificate of Analysis (COA) may provide information relating to the identity, measured content and reported purity of a tested batch. Researchers should review the actual documentation associated with their specific product batch. A nominal 5mg label describes the stated product quantity and does not independently confirm analytical content or purity. Analytical methods relevant to peptide research include high-performance liquid chromatography (HPLC) and mass spectrometry (MS). These methods can provide different types of information about peptide samples. For further information on laboratory research materials and analytical transparency, explore the N&A Peptides website.

Eloralintide 5mg Pen Storage and Handling

Research peptides require appropriate storage and handling to protect sample integrity.

• Follow the storage requirements documented for the specific supplied batch.
• Keep materials in their original, clearly identified packaging.
• Protect research samples from unsuitable environmental conditions.
• Use appropriate laboratory safety procedures and sample tracking records.
• Restrict access to qualified laboratory personnel.

Any product-specific refrigeration or temperature instructions should be confirmed against the supplier's batch documentation rather than inferred solely from published clinical studies.

Research Resources and Further Reading

For researchers reviewing eloralintide, selective amylin receptor agonists and related scientific literature, the following references provide useful starting points:

• Eli Lilly – What to Know About Eloralintide
• PubMed – Eloralintide Phase 2 Clinical Trial
• Eli Lilly – ENLIGHTEN-6 Phase 3 Research Study
• N&A Peptides – Retatrutide 40mg Pen Research Information

Important Research Disclaimer

Eloralintide 5mg Pen is intended strictly for laboratory, analytical and scientific research purposes only. NOT FOR HUMAN OR VETERINARY CONSUMPTION. Eloralintide is an investigational compound and is not an approved medicine. This product is not intended for diagnosis, treatment, prevention or management of any disease or medical condition. All information is provided for research and educational purposes and does not constitute medical advice, administration guidance or a recommendation for personal use.